Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease

The relationship between <i<Helicobacter pylori</i< infection and/or gastric disorders and chronic kidney disease (CKD) has not been elucidated. We investigated the relationship between <i<Helicobacter pylori</i< and/or atrophic gastritis (AG) and chronic kidney disease. In t...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Koichi Hata [verfasserIn] Teruhide Koyama [verfasserIn] Etsuko Ozaki [verfasserIn] Nagato Kuriyama [verfasserIn] Shigeto Mizuno [verfasserIn] Daisuke Matsui [verfasserIn] Isao Watanabe [verfasserIn] Ritei Uehara [verfasserIn] Yoshiyuki Watanabe [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	atrophic gastritis chronic kidney disease inter-organ interactions

Übergeordnetes Werk:	In: Healthcare - MDPI AG, 2013, 9(2021), 2, p 162
Übergeordnetes Werk:	volume:9 ; year:2021 ; number:2, p 162

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/healthcare9020162

Katalog-ID:	DOAJ078409314

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ078409314
003	DE-627
005	20240414083439.0
007	cr uuu---uuuuu
008	230228s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/healthcare9020162 \|2 doi
035			\|a (DE-627)DOAJ078409314
035			\|a (DE-599)DOAJ407d9277602346f68b229f83a31186b5
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a Koichi Hata \|e verfasserin \|4 aut
245	1	0	\|a Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The relationship between <i<Helicobacter pylori</i< infection and/or gastric disorders and chronic kidney disease (CKD) has not been elucidated. We investigated the relationship between <i<Helicobacter pylori</i< and/or atrophic gastritis (AG) and chronic kidney disease. In total, 3560 participants (1127 men and 2433 women) were eligible for this cross-sectional study. We divided participants into four study groups: with/without <i<Helicobacter pylori</i< infection and with/without AG. The HP (+) AG (−) group demonstrated a significant association with CKD compared with the HP (−) AG (−) group (adjusted odds ratio, 1.443; 95% confidence interval, 1.047–1.989). In contrast, the HP (+) AG (+) group showed significantly lower adjusted odds of CKD than the HP (−) AG (−) group (adjusted odds ratio, 0.608; 95% confidence interval, 0.402–0.920). <i<H. pylori</i< infection without AG might be associated with CKD in these participants. Conversely, the HP (+) AG (+) group had lower odds of CKD. Uncovering an association between gastric and renal conditions could lead to development of new treatment strategies.
650		4	\|a atrophic gastritis
650		4	\|a chronic kidney disease
650		4	\|a <i<Helicobacter pylori</i<
650		4	\|a inter-organ interactions
653		0	\|a Medicine
653		0	\|a R
700	0		\|a Teruhide Koyama \|e verfasserin \|4 aut
700	0		\|a Etsuko Ozaki \|e verfasserin \|4 aut
700	0		\|a Nagato Kuriyama \|e verfasserin \|4 aut
700	0		\|a Shigeto Mizuno \|e verfasserin \|4 aut
700	0		\|a Daisuke Matsui \|e verfasserin \|4 aut
700	0		\|a Isao Watanabe \|e verfasserin \|4 aut
700	0		\|a Ritei Uehara \|e verfasserin \|4 aut
700	0		\|a Yoshiyuki Watanabe \|e verfasserin \|4 aut
773	0	8	\|i In \|t Healthcare \|d MDPI AG, 2013 \|g 9(2021), 2, p 162 \|w (DE-627)750371544 \|w (DE-600)2721009-1 \|x 22279032 \|7 nnns
773	1	8	\|g volume:9 \|g year:2021 \|g number:2, p 162
856	4	0	\|u https://doi.org/10.3390/healthcare9020162 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/407d9277602346f68b229f83a31186b5 \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2227-9032/9/2/162 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2227-9032 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 9 \|j 2021 \|e 2, p 162

Indexfelder

author_variant	k h kh t k tk e o eo n k nk s m sm d m dm i w iw r u ru y w yw
matchkey_str	article:22279032:2021----::sesnteeainhpeweieioatryoiad
hierarchy_sort_str	2021
publishDate	2021
allfields	10.3390/healthcare9020162 doi (DE-627)DOAJ078409314 (DE-599)DOAJ407d9277602346f68b229f83a31186b5 DE-627 ger DE-627 rakwb eng Koichi Hata verfasserin aut Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The relationship between <i<Helicobacter pylori</i< infection and/or gastric disorders and chronic kidney disease (CKD) has not been elucidated. We investigated the relationship between <i<Helicobacter pylori</i< and/or atrophic gastritis (AG) and chronic kidney disease. In total, 3560 participants (1127 men and 2433 women) were eligible for this cross-sectional study. We divided participants into four study groups: with/without <i<Helicobacter pylori</i< infection and with/without AG. The HP (+) AG (−) group demonstrated a significant association with CKD compared with the HP (−) AG (−) group (adjusted odds ratio, 1.443; 95% confidence interval, 1.047–1.989). In contrast, the HP (+) AG (+) group showed significantly lower adjusted odds of CKD than the HP (−) AG (−) group (adjusted odds ratio, 0.608; 95% confidence interval, 0.402–0.920). <i<H. pylori</i< infection without AG might be associated with CKD in these participants. Conversely, the HP (+) AG (+) group had lower odds of CKD. Uncovering an association between gastric and renal conditions could lead to development of new treatment strategies. atrophic gastritis chronic kidney disease <i<Helicobacter pylori</i< inter-organ interactions Medicine R Teruhide Koyama verfasserin aut Etsuko Ozaki verfasserin aut Nagato Kuriyama verfasserin aut Shigeto Mizuno verfasserin aut Daisuke Matsui verfasserin aut Isao Watanabe verfasserin aut Ritei Uehara verfasserin aut Yoshiyuki Watanabe verfasserin aut In Healthcare MDPI AG, 2013 9(2021), 2, p 162 (DE-627)750371544 (DE-600)2721009-1 22279032 nnns volume:9 year:2021 number:2, p 162 https://doi.org/10.3390/healthcare9020162 kostenfrei https://doaj.org/article/407d9277602346f68b229f83a31186b5 kostenfrei https://www.mdpi.com/2227-9032/9/2/162 kostenfrei https://doaj.org/toc/2227-9032 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 2, p 162
spelling	10.3390/healthcare9020162 doi (DE-627)DOAJ078409314 (DE-599)DOAJ407d9277602346f68b229f83a31186b5 DE-627 ger DE-627 rakwb eng Koichi Hata verfasserin aut Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The relationship between <i<Helicobacter pylori</i< infection and/or gastric disorders and chronic kidney disease (CKD) has not been elucidated. We investigated the relationship between <i<Helicobacter pylori</i< and/or atrophic gastritis (AG) and chronic kidney disease. In total, 3560 participants (1127 men and 2433 women) were eligible for this cross-sectional study. We divided participants into four study groups: with/without <i<Helicobacter pylori</i< infection and with/without AG. The HP (+) AG (−) group demonstrated a significant association with CKD compared with the HP (−) AG (−) group (adjusted odds ratio, 1.443; 95% confidence interval, 1.047–1.989). In contrast, the HP (+) AG (+) group showed significantly lower adjusted odds of CKD than the HP (−) AG (−) group (adjusted odds ratio, 0.608; 95% confidence interval, 0.402–0.920). <i<H. pylori</i< infection without AG might be associated with CKD in these participants. Conversely, the HP (+) AG (+) group had lower odds of CKD. Uncovering an association between gastric and renal conditions could lead to development of new treatment strategies. atrophic gastritis chronic kidney disease <i<Helicobacter pylori</i< inter-organ interactions Medicine R Teruhide Koyama verfasserin aut Etsuko Ozaki verfasserin aut Nagato Kuriyama verfasserin aut Shigeto Mizuno verfasserin aut Daisuke Matsui verfasserin aut Isao Watanabe verfasserin aut Ritei Uehara verfasserin aut Yoshiyuki Watanabe verfasserin aut In Healthcare MDPI AG, 2013 9(2021), 2, p 162 (DE-627)750371544 (DE-600)2721009-1 22279032 nnns volume:9 year:2021 number:2, p 162 https://doi.org/10.3390/healthcare9020162 kostenfrei https://doaj.org/article/407d9277602346f68b229f83a31186b5 kostenfrei https://www.mdpi.com/2227-9032/9/2/162 kostenfrei https://doaj.org/toc/2227-9032 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 2, p 162
allfields_unstemmed	10.3390/healthcare9020162 doi (DE-627)DOAJ078409314 (DE-599)DOAJ407d9277602346f68b229f83a31186b5 DE-627 ger DE-627 rakwb eng Koichi Hata verfasserin aut Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The relationship between <i<Helicobacter pylori</i< infection and/or gastric disorders and chronic kidney disease (CKD) has not been elucidated. We investigated the relationship between <i<Helicobacter pylori</i< and/or atrophic gastritis (AG) and chronic kidney disease. In total, 3560 participants (1127 men and 2433 women) were eligible for this cross-sectional study. We divided participants into four study groups: with/without <i<Helicobacter pylori</i< infection and with/without AG. The HP (+) AG (−) group demonstrated a significant association with CKD compared with the HP (−) AG (−) group (adjusted odds ratio, 1.443; 95% confidence interval, 1.047–1.989). In contrast, the HP (+) AG (+) group showed significantly lower adjusted odds of CKD than the HP (−) AG (−) group (adjusted odds ratio, 0.608; 95% confidence interval, 0.402–0.920). <i<H. pylori</i< infection without AG might be associated with CKD in these participants. Conversely, the HP (+) AG (+) group had lower odds of CKD. Uncovering an association between gastric and renal conditions could lead to development of new treatment strategies. atrophic gastritis chronic kidney disease <i<Helicobacter pylori</i< inter-organ interactions Medicine R Teruhide Koyama verfasserin aut Etsuko Ozaki verfasserin aut Nagato Kuriyama verfasserin aut Shigeto Mizuno verfasserin aut Daisuke Matsui verfasserin aut Isao Watanabe verfasserin aut Ritei Uehara verfasserin aut Yoshiyuki Watanabe verfasserin aut In Healthcare MDPI AG, 2013 9(2021), 2, p 162 (DE-627)750371544 (DE-600)2721009-1 22279032 nnns volume:9 year:2021 number:2, p 162 https://doi.org/10.3390/healthcare9020162 kostenfrei https://doaj.org/article/407d9277602346f68b229f83a31186b5 kostenfrei https://www.mdpi.com/2227-9032/9/2/162 kostenfrei https://doaj.org/toc/2227-9032 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 2, p 162
allfieldsGer	10.3390/healthcare9020162 doi (DE-627)DOAJ078409314 (DE-599)DOAJ407d9277602346f68b229f83a31186b5 DE-627 ger DE-627 rakwb eng Koichi Hata verfasserin aut Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The relationship between <i<Helicobacter pylori</i< infection and/or gastric disorders and chronic kidney disease (CKD) has not been elucidated. We investigated the relationship between <i<Helicobacter pylori</i< and/or atrophic gastritis (AG) and chronic kidney disease. In total, 3560 participants (1127 men and 2433 women) were eligible for this cross-sectional study. We divided participants into four study groups: with/without <i<Helicobacter pylori</i< infection and with/without AG. The HP (+) AG (−) group demonstrated a significant association with CKD compared with the HP (−) AG (−) group (adjusted odds ratio, 1.443; 95% confidence interval, 1.047–1.989). In contrast, the HP (+) AG (+) group showed significantly lower adjusted odds of CKD than the HP (−) AG (−) group (adjusted odds ratio, 0.608; 95% confidence interval, 0.402–0.920). <i<H. pylori</i< infection without AG might be associated with CKD in these participants. Conversely, the HP (+) AG (+) group had lower odds of CKD. Uncovering an association between gastric and renal conditions could lead to development of new treatment strategies. atrophic gastritis chronic kidney disease <i<Helicobacter pylori</i< inter-organ interactions Medicine R Teruhide Koyama verfasserin aut Etsuko Ozaki verfasserin aut Nagato Kuriyama verfasserin aut Shigeto Mizuno verfasserin aut Daisuke Matsui verfasserin aut Isao Watanabe verfasserin aut Ritei Uehara verfasserin aut Yoshiyuki Watanabe verfasserin aut In Healthcare MDPI AG, 2013 9(2021), 2, p 162 (DE-627)750371544 (DE-600)2721009-1 22279032 nnns volume:9 year:2021 number:2, p 162 https://doi.org/10.3390/healthcare9020162 kostenfrei https://doaj.org/article/407d9277602346f68b229f83a31186b5 kostenfrei https://www.mdpi.com/2227-9032/9/2/162 kostenfrei https://doaj.org/toc/2227-9032 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 2, p 162
allfieldsSound	10.3390/healthcare9020162 doi (DE-627)DOAJ078409314 (DE-599)DOAJ407d9277602346f68b229f83a31186b5 DE-627 ger DE-627 rakwb eng Koichi Hata verfasserin aut Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The relationship between <i<Helicobacter pylori</i< infection and/or gastric disorders and chronic kidney disease (CKD) has not been elucidated. We investigated the relationship between <i<Helicobacter pylori</i< and/or atrophic gastritis (AG) and chronic kidney disease. In total, 3560 participants (1127 men and 2433 women) were eligible for this cross-sectional study. We divided participants into four study groups: with/without <i<Helicobacter pylori</i< infection and with/without AG. The HP (+) AG (−) group demonstrated a significant association with CKD compared with the HP (−) AG (−) group (adjusted odds ratio, 1.443; 95% confidence interval, 1.047–1.989). In contrast, the HP (+) AG (+) group showed significantly lower adjusted odds of CKD than the HP (−) AG (−) group (adjusted odds ratio, 0.608; 95% confidence interval, 0.402–0.920). <i<H. pylori</i< infection without AG might be associated with CKD in these participants. Conversely, the HP (+) AG (+) group had lower odds of CKD. Uncovering an association between gastric and renal conditions could lead to development of new treatment strategies. atrophic gastritis chronic kidney disease <i<Helicobacter pylori</i< inter-organ interactions Medicine R Teruhide Koyama verfasserin aut Etsuko Ozaki verfasserin aut Nagato Kuriyama verfasserin aut Shigeto Mizuno verfasserin aut Daisuke Matsui verfasserin aut Isao Watanabe verfasserin aut Ritei Uehara verfasserin aut Yoshiyuki Watanabe verfasserin aut In Healthcare MDPI AG, 2013 9(2021), 2, p 162 (DE-627)750371544 (DE-600)2721009-1 22279032 nnns volume:9 year:2021 number:2, p 162 https://doi.org/10.3390/healthcare9020162 kostenfrei https://doaj.org/article/407d9277602346f68b229f83a31186b5 kostenfrei https://www.mdpi.com/2227-9032/9/2/162 kostenfrei https://doaj.org/toc/2227-9032 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 2, p 162
language	English
source	In Healthcare 9(2021), 2, p 162 volume:9 year:2021 number:2, p 162
sourceStr	In Healthcare 9(2021), 2, p 162 volume:9 year:2021 number:2, p 162
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	atrophic gastritis chronic kidney disease <i<Helicobacter pylori</i< inter-organ interactions Medicine R
isfreeaccess_bool	true
container_title	Healthcare
authorswithroles_txt_mv	Koichi Hata @@aut@@ Teruhide Koyama @@aut@@ Etsuko Ozaki @@aut@@ Nagato Kuriyama @@aut@@ Shigeto Mizuno @@aut@@ Daisuke Matsui @@aut@@ Isao Watanabe @@aut@@ Ritei Uehara @@aut@@ Yoshiyuki Watanabe @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	750371544
id	DOAJ078409314
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ078409314</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414083439.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/healthcare9020162</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ078409314</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ407d9277602346f68b229f83a31186b5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Koichi Hata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The relationship between <i<Helicobacter pylori</i< infection and/or gastric disorders and chronic kidney disease (CKD) has not been elucidated. We investigated the relationship between <i<Helicobacter pylori</i< and/or atrophic gastritis (AG) and chronic kidney disease. In total, 3560 participants (1127 men and 2433 women) were eligible for this cross-sectional study. We divided participants into four study groups: with/without <i<Helicobacter pylori</i< infection and with/without AG. The HP (+) AG (−) group demonstrated a significant association with CKD compared with the HP (−) AG (−) group (adjusted odds ratio, 1.443; 95% confidence interval, 1.047–1.989). In contrast, the HP (+) AG (+) group showed significantly lower adjusted odds of CKD than the HP (−) AG (−) group (adjusted odds ratio, 0.608; 95% confidence interval, 0.402–0.920). <i<H. pylori</i< infection without AG might be associated with CKD in these participants. Conversely, the HP (+) AG (+) group had lower odds of CKD. Uncovering an association between gastric and renal conditions could lead to development of new treatment strategies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">atrophic gastritis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic kidney disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<Helicobacter pylori</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inter-organ interactions</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Teruhide Koyama</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Etsuko Ozaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nagato Kuriyama</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shigeto Mizuno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daisuke Matsui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isao Watanabe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ritei Uehara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshiyuki Watanabe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Healthcare</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">9(2021), 2, p 162</subfield><subfield code="w">(DE-627)750371544</subfield><subfield code="w">(DE-600)2721009-1</subfield><subfield code="x">22279032</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:2, p 162</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/healthcare9020162</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/407d9277602346f68b229f83a31186b5</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2227-9032/9/2/162</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2227-9032</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2021</subfield><subfield code="e">2, p 162</subfield></datafield></record></collection>
author	Koichi Hata
spellingShingle	Koichi Hata misc atrophic gastritis misc chronic kidney disease misc <i<Helicobacter pylori</i< misc inter-organ interactions misc Medicine misc R Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease
authorStr	Koichi Hata
ppnlink_with_tag_str_mv	@@773@@(DE-627)750371544
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	22279032
topic_title	Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease atrophic gastritis chronic kidney disease <i<Helicobacter pylori</i< inter-organ interactions
topic	misc atrophic gastritis misc chronic kidney disease misc <i<Helicobacter pylori</i< misc inter-organ interactions misc Medicine misc R
topic_unstemmed	misc atrophic gastritis misc chronic kidney disease misc <i<Helicobacter pylori</i< misc inter-organ interactions misc Medicine misc R
topic_browse	misc atrophic gastritis misc chronic kidney disease misc <i<Helicobacter pylori</i< misc inter-organ interactions misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Healthcare
hierarchy_parent_id	750371544
hierarchy_top_title	Healthcare
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)750371544 (DE-600)2721009-1
title	Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease
ctrlnum	(DE-627)DOAJ078409314 (DE-599)DOAJ407d9277602346f68b229f83a31186b5
title_full	Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease
author_sort	Koichi Hata
journal	Healthcare
journalStr	Healthcare
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
author_browse	Koichi Hata Teruhide Koyama Etsuko Ozaki Nagato Kuriyama Shigeto Mizuno Daisuke Matsui Isao Watanabe Ritei Uehara Yoshiyuki Watanabe
container_volume	9
format_se	Elektronische Aufsätze
author-letter	Koichi Hata
doi_str_mv	10.3390/healthcare9020162
author2-role	verfasserin
title_sort	assessing the relationship between <i<helicobacter pylori</i< and chronic kidney disease
title_auth	Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease
abstract	The relationship between <i<Helicobacter pylori</i< infection and/or gastric disorders and chronic kidney disease (CKD) has not been elucidated. We investigated the relationship between <i<Helicobacter pylori</i< and/or atrophic gastritis (AG) and chronic kidney disease. In total, 3560 participants (1127 men and 2433 women) were eligible for this cross-sectional study. We divided participants into four study groups: with/without <i<Helicobacter pylori</i< infection and with/without AG. The HP (+) AG (−) group demonstrated a significant association with CKD compared with the HP (−) AG (−) group (adjusted odds ratio, 1.443; 95% confidence interval, 1.047–1.989). In contrast, the HP (+) AG (+) group showed significantly lower adjusted odds of CKD than the HP (−) AG (−) group (adjusted odds ratio, 0.608; 95% confidence interval, 0.402–0.920). <i<H. pylori</i< infection without AG might be associated with CKD in these participants. Conversely, the HP (+) AG (+) group had lower odds of CKD. Uncovering an association between gastric and renal conditions could lead to development of new treatment strategies.
abstractGer	The relationship between <i<Helicobacter pylori</i< infection and/or gastric disorders and chronic kidney disease (CKD) has not been elucidated. We investigated the relationship between <i<Helicobacter pylori</i< and/or atrophic gastritis (AG) and chronic kidney disease. In total, 3560 participants (1127 men and 2433 women) were eligible for this cross-sectional study. We divided participants into four study groups: with/without <i<Helicobacter pylori</i< infection and with/without AG. The HP (+) AG (−) group demonstrated a significant association with CKD compared with the HP (−) AG (−) group (adjusted odds ratio, 1.443; 95% confidence interval, 1.047–1.989). In contrast, the HP (+) AG (+) group showed significantly lower adjusted odds of CKD than the HP (−) AG (−) group (adjusted odds ratio, 0.608; 95% confidence interval, 0.402–0.920). <i<H. pylori</i< infection without AG might be associated with CKD in these participants. Conversely, the HP (+) AG (+) group had lower odds of CKD. Uncovering an association between gastric and renal conditions could lead to development of new treatment strategies.
abstract_unstemmed	The relationship between <i<Helicobacter pylori</i< infection and/or gastric disorders and chronic kidney disease (CKD) has not been elucidated. We investigated the relationship between <i<Helicobacter pylori</i< and/or atrophic gastritis (AG) and chronic kidney disease. In total, 3560 participants (1127 men and 2433 women) were eligible for this cross-sectional study. We divided participants into four study groups: with/without <i<Helicobacter pylori</i< infection and with/without AG. The HP (+) AG (−) group demonstrated a significant association with CKD compared with the HP (−) AG (−) group (adjusted odds ratio, 1.443; 95% confidence interval, 1.047–1.989). In contrast, the HP (+) AG (+) group showed significantly lower adjusted odds of CKD than the HP (−) AG (−) group (adjusted odds ratio, 0.608; 95% confidence interval, 0.402–0.920). <i<H. pylori</i< infection without AG might be associated with CKD in these participants. Conversely, the HP (+) AG (+) group had lower odds of CKD. Uncovering an association between gastric and renal conditions could lead to development of new treatment strategies.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2, p 162
title_short	Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease
url	https://doi.org/10.3390/healthcare9020162 https://doaj.org/article/407d9277602346f68b229f83a31186b5 https://www.mdpi.com/2227-9032/9/2/162 https://doaj.org/toc/2227-9032
remote_bool	true
author2	Teruhide Koyama Etsuko Ozaki Nagato Kuriyama Shigeto Mizuno Daisuke Matsui Isao Watanabe Ritei Uehara Yoshiyuki Watanabe
author2Str	Teruhide Koyama Etsuko Ozaki Nagato Kuriyama Shigeto Mizuno Daisuke Matsui Isao Watanabe Ritei Uehara Yoshiyuki Watanabe
ppnlink	750371544
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/healthcare9020162
up_date	2024-07-03T17:48:16.234Z
_version_	1803581019904802817
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ078409314</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414083439.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/healthcare9020162</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ078409314</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ407d9277602346f68b229f83a31186b5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Koichi Hata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The relationship between <i<Helicobacter pylori</i< infection and/or gastric disorders and chronic kidney disease (CKD) has not been elucidated. We investigated the relationship between <i<Helicobacter pylori</i< and/or atrophic gastritis (AG) and chronic kidney disease. In total, 3560 participants (1127 men and 2433 women) were eligible for this cross-sectional study. We divided participants into four study groups: with/without <i<Helicobacter pylori</i< infection and with/without AG. The HP (+) AG (−) group demonstrated a significant association with CKD compared with the HP (−) AG (−) group (adjusted odds ratio, 1.443; 95% confidence interval, 1.047–1.989). In contrast, the HP (+) AG (+) group showed significantly lower adjusted odds of CKD than the HP (−) AG (−) group (adjusted odds ratio, 0.608; 95% confidence interval, 0.402–0.920). <i<H. pylori</i< infection without AG might be associated with CKD in these participants. Conversely, the HP (+) AG (+) group had lower odds of CKD. Uncovering an association between gastric and renal conditions could lead to development of new treatment strategies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">atrophic gastritis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic kidney disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<Helicobacter pylori</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inter-organ interactions</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Teruhide Koyama</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Etsuko Ozaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nagato Kuriyama</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shigeto Mizuno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daisuke Matsui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isao Watanabe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ritei Uehara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshiyuki Watanabe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Healthcare</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">9(2021), 2, p 162</subfield><subfield code="w">(DE-627)750371544</subfield><subfield code="w">(DE-600)2721009-1</subfield><subfield code="x">22279032</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:2, p 162</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/healthcare9020162</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/407d9277602346f68b229f83a31186b5</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2227-9032/9/2/162</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2227-9032</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2021</subfield><subfield code="e">2, p 162</subfield></datafield></record></collection>
score	7.4006567

Nicht das Richtige dabei?

Schreiben Sie uns!

Assessing the Relationship between <i<Helicobacter pylori</i< and Chronic Kidney Disease

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?